Catalyze Interviews Vector Bioscience’s CEO, Lluna Gallego, on Advancing RNA Delivery in Oncology
We are pleased to share a recent interview with our CEO and Co-Founder, Lluna Gallego, conducted by Catalyze,
March 6, 2026
News
The Nobel Prize for MOFs: A milestone for reticular chemistry and for the future of drug delivery
This year’s Nobel Prize in Chemistry has been awarded to the pioneers of MOFs, recognising a class of
February 6, 2026
Vector Bioscience Cambridge Joins the Future Medicines Accelerator
Vector Bioscience Cambridge has been selected to join the Future Medicines Accelerator, a programme delivered by LYVA Labs
November 12, 2025
Advancing Nanomedicine Through Collaboration: Profiling the Safety of Metal–Organic Frameworks
At Vector Bioscience Cambridge, we work in close collaboration with Prof. David Fairen-Jimenez’s research group at the University
August 14, 2025
Advancing a New Therapeutic Approach for Mesothelioma Through Collaboration
Vector Bioscience Cambridge has established a new collaboration with researchers from the University of Glasgow to develop and
July 11, 2025
Vector Bioscience Cambridge joins the Milner Therapeutics Institute Affiliate Scheme
We are pleased to announce that Vector Bioscience Cambridge has joined the Milner Therapeutics Institute as an Affiliated
July 9, 2025
Vector Bioscience Cambridge Joins EU4MOFs COST Action Network
We are pleased to announce that Vector Bioscience Cambridge has joined the EU4MOFs COST Action network, a European
May 28, 2025
Vector Bioscience Cambridge joins the BioIndustry Association (BIA)
We are pleased to announce that Vector Bioscience Cambridge is now an official member of the BioIndustry Association
May 26, 2025
Business Weekly Awards 2024
Vector Bioscience Shortlisted for Business Weekly Awards 2024 We are delighted to share that Vector Bioscience Cambridge was
January 14, 2025